Trial Profile
A Randomised, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients With Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Codrituzumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical; Roche
- 30 Jan 2018 Results (n=181) of a study assessing clinically relevant factors that affect the overall survival by using time to event model published in the British Journal of Clinical Pharmacology
- 20 Apr 2016 Results (n = 113)presented at the 107th Annual Meeting of the American Association for Cancer Research.
- 13 Apr 2016 Primary endpoint of progression-free survival has not been met, according to results published in the Journal of Hepatology.